Richard Law
Stock Analyst at Goldman Sachs
(1.87)
# 2,963
Out of 4,829 analysts
63
Total ratings
50%
Success rate
3.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $3.70 | -18.92% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $6.99 | +85.98% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $18.33 | +69.12% | 3 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $31 → $27 | $12.39 | +117.92% | 3 | May 7, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $30 | $27.55 | +8.89% | 1 | Apr 8, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $82 → $73 | $38.39 | +90.18% | 3 | Feb 27, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $28 → $24 | $14.60 | +64.38% | 6 | Feb 13, 2025 | |
| MRUS Merus | Initiates: Buy | $73 | $40.90 | +78.48% | 1 | Nov 21, 2024 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $24 | $4.60 | +421.74% | 4 | Apr 2, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Neutral | $11 | $4.09 | +168.95% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $31 | $4.23 | +632.86% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $17.41 | +169.96% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $35.62 | +76.87% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $30.07 | +23.05% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $8.12 | +835.96% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $1.45 | +865.52% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $6.61 | +822.84% | 4 | May 8, 2023 |
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $3.70
Upside: -18.92%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $6.99
Upside: +85.98%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $18.33
Upside: +69.12%
Viridian Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $31 → $27
Current: $12.39
Upside: +117.92%
Viking Therapeutics
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $27.55
Upside: +8.89%
MoonLake Immunotherapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $82 → $73
Current: $38.39
Upside: +90.18%
Mineralys Therapeutics
Feb 13, 2025
Maintains: Buy
Price Target: $28 → $24
Current: $14.60
Upside: +64.38%
Merus
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $40.90
Upside: +78.48%
Olema Pharmaceuticals
Apr 2, 2024
Initiates: Buy
Price Target: $24
Current: $4.60
Upside: +421.74%
Monte Rosa Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $4.09
Upside: +168.95%
Aug 11, 2023
Reiterates: Neutral
Price Target: $31
Current: $4.23
Upside: +632.86%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $17.41
Upside: +169.96%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $35.62
Upside: +76.87%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $30.07
Upside: +23.05%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $8.12
Upside: +835.96%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $1.45
Upside: +865.52%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $6.61
Upside: +822.84%